A protein switched on after a heart attack deepened the injury by breaking mitochondrial fuel use — in male mice
Edited by Samael A. Tejada, Founder & Editor-in-Chief
·Tip: press play, then lock your phone or switch apps — the article keeps reading.
The enzyme TRIM47 is switched on in heart-muscle cells during ischemia/reperfusion injury and drives mitochondrial dysfunction and defective fatty-acid burning through a FOXO1/HNF4-alpha pathway, a Nature Communications study in male mice found (November 14, 2026). Blocking it after injury protected the heart in mice; no human evidence exists.
Reperfusion injury is cardiology's cruel trade: the treatment that saves the heart also wounds it. This study identifies one of the wound's authors — and shows the damage is still negotiable after the event.
What did the researchers find?
TRIM47 — an E3 ubiquitin ligase, an enzyme that tags other proteins — is markedly upregulated in cardiomyocytes during cardiac ischemia/reperfusion injury, switched on via early growth response 1, and its level positively correlates with injury severity. Cardiomyocyte-specific overexpression worsened injury, remodelling and dysfunction in living mice and in cultured heart cells; knockout attenuated all three.
How does TRIM47 damage mitochondria?
By rerouting a metabolic regulator. TRIM47 promotes a specific (K63-linked) ubiquitination of FOXO1 at one site (K210), driving FOXO1 into the nucleus, where it binds HNF4-alpha and suppresses its transcriptional activity. The downstream result is mitochondrial dysfunction and defects in fatty-acid oxidation — the heart's preferred fuel pathway — precisely when the reperfused heart most needs clean energy production.
Could this become a treatment?
The encouraging signal is timing: therapeutic knockdown of TRIM47 after the injury still prevented cardiac remodelling and dysfunction in the mice. But every result here is in male mice and cell models. There is no human data, no drug, and no evidence the same axis dominates human reperfusion injury. It is a named, testable target — nothing more, and that is still valuable.
Frequently asked questions
What is reperfusion injury?
Damage that occurs when blood flow returns to tissue after a blockage — for example when a heart artery is reopened after a heart attack. The returning oxygen triggers inflammation and mitochondrial stress that kill some cells the blockage itself spared.
What is an E3 ubiquitin ligase?
An enzyme that attaches ubiquitin tags to specific proteins, changing their location, activity or lifespan. TRIM47 is one such tagger; this study shows what it tags in the injured heart.
Was this tested in people?
No. The in-vivo work was in male mice, supported by cell experiments. Human relevance is untested.
Where the evidence stands
- Established: Reperfusion after a heart attack causes additional injury, and mitochondrial dysfunction and impaired fatty-acid oxidation are central features of the damaged heart's metabolism.
- Preliminary: The TRIM47/FOXO1/HNF4-alpha axis itself: one study (Nature Communications, 2026) with mouse genetics and a post-injury intervention, in male mice.
- Absent: Evidence in female animals or in people, and any therapy targeting TRIM47.
Join the discussion
To get the conversation started: What questions does this story raise for you? Share them below — every comment is reviewed by our moderators before it appears.
Community discussion only — not medical advice. Every comment is reviewed by our moderators before it appears. Sign in with Google or a free Hyvor account to join in.